Skip to main content

Innovation was one of the key themes at ECR2024 and it is also one of the major concerns for Bracco, Fabio Tedoldi, Head of Global Research & Development at Bracco Imaging, told Mélisande Rouger last month in Vienna.

Bracco has launched a number of significant advances since the 1980s – the first non ionic contrast agent for x-ray in 1981, the first high-relaxation for MRI in the 1990s, and, in the 2000s, the ultrasound contrast agent with the largest number of indications until today.

In 2022 and 2023 Bracco launched a second generation MR agent with superiority relativity and a PSMA PET agent, and the company is continuing its efforts to further innovate.
‘With MR, we are working on contrast media with different pragmatic metals in order to make them more sustainable,’ he said. ‘In PET, we don’t only want to target PSMA, but also, for instance, the fibroblast activation protein, and we want to move ultrasound into the era of precision medicine.’

Bracco is looking forward to meeting the future challenges in healthcare, he added. ‘The aging population will lead to more examinations to take care of older people, and a reduced number of people paying for that,’ he said. ‘Any patient that needs a contrast-enhanced procedure must have the procedure (…) In our manufacturing, we have to adopt very innovative processes and we have to make it all sustainable.’